Article
Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.
Medicine - 1 May 2017
Zick Aviad, Peretz Tamar, Lotem Michal, Hubert Ayala, Katz Daniela, Temper Mark, Rottenberg Yakir, Uziely Beatrice, Nechushtan Hovav, Meirovitz Amichai, Sonnenblick Amir, Sapir Eli, Edelman David, Goldberg Yael, Lossos Alexander, Rosenberg Shai, Fried Iris, Finklstein Ruth, Pikarsky Eli, Goldshmidt Hanoch
Abstract excerpt
Molecular portraits of numerous tumors have flooded oncologists with vast amounts of data. In parallel, effective inhibitors of central pathways have shown great clinical benefit. Together, this promises potential clinical benefits to otherwise end-stage cancer patients. Here, we report a clinical service offering mutation detection of archived samples using the ion Ampliseq cancer panel coupled with clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.